AAIC Roundup: Alzheimer’s, Seizures, Sleep Medication, the LGBT Community and MoreAllbiopro2019-07-20T23:23:13+09:007월 20th, 2019|
Gilead Snaps up Antiviral Programs From Novartis, Follows Slew of Other Pipeline-Bolstering DealsAllbiopro2019-07-20T23:22:16+09:007월 20th, 2019|
FiercePharmaAsia—Takeda’s €1.5B drug sale; Indian drugmakers in China; Eisai’s Alzheimer’s testAllbiopro2019-07-20T23:21:21+09:007월 20th, 2019|
As filgotinib filing nears, Gilead should nab Celgene’s Otezla, analysts say. Here’s whyAllbiopro2019-07-20T23:20:25+09:007월 20th, 2019|
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. marketAllbiopro2019-07-20T23:19:28+09:007월 20th, 2019|
Ditch the opioid ‘negotiating class’ proposal, experts say. State attorneys general are better suited to reach a dealAllbiopro2019-07-20T23:18:46+09:007월 20th, 2019|
Pfizer’s keys to juggling 8 U.S. launches? Organization, accountability, clear goalsAllbiopro2019-07-20T23:18:10+09:007월 20th, 2019|
How a faulty gene that drives muscular dystrophy also shields cancer cells from immunotherapyAllbiopro2019-07-20T23:17:36+09:007월 20th, 2019|
Chutes & Ladders—Gilead CEO continues top-level revamp with 3 more exec exitsAllbiopro2019-07-20T23:17:01+09:007월 20th, 2019|
Mallinckrodt strikes $20M RNAi pact with Silence TherapeuticsAllbiopro2019-07-20T23:16:26+09:007월 20th, 2019|
Pall to provide ‘A-Z of single-use tech’ in Servier dealAllbiopro2019-07-20T23:15:26+09:007월 20th, 2019|
Order of the Pfenex: From CDMO, to biosimilars, to novel biologicsAllbiopro2019-07-20T23:14:53+09:007월 20th, 2019|
‘Semi-synthetic’ bacteria churn out unnatural proteinsAllbiopro2019-07-20T23:14:19+09:007월 20th, 2019|
‘Trojan horse’ anticancer drug disguises itself as fatAllbiopro2019-07-20T23:13:46+09:007월 20th, 2019|
Merck and Broad Institute Announce CRISPR License Framework to Encourage InnovationAllbiopro2019-07-20T23:12:41+09:007월 20th, 2019|
Making cancer stem cells visible to the immune systemAllbiopro2019-07-20T23:12:07+09:007월 20th, 2019|
